# Binimetinib in Patients With BRAF Fusion-positive Low-grade Glioma or Pancreatic Cancer (Perfume)

Source: https://onco.cc/trials/nct06159478/  
OnCo record `nct06159478` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial in pancreatic cancer, run by National Cancer Center, Japan, now recruiting.

## Summary

Binimetinib in Patients With BRAF Fusion-positive Low-grade Glioma or Pancreatic Cancer (Perfume) is a phase 2, interventional study registered as NCT06159478 by National Cancer Center, Japan, with a registry enrolment figure of 32 participants, started 2023-03-29 and due to reach its primary completion in 2027-02-28. Interventions recorded: Binimetinib 15 MG. Conditions listed: Low-grade Glioma; Pancreatic Cancer. Primary outcome: Overall response rate (centrally assessed). Pancreatic eligibility wording from the registry: "Cohort B 19) Histopathologically diagnosed as pancreatic cancer (histologically not specified)". Sites: Japan. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-24
- Also known as: Perfume
- Tags: ctgov-ingest; pancreatic-deep-dive
- Registry id: NCT06159478
- Phase: 2
- Setting: Phase II Investigator-initiated Trial of Binimetinib in Patients With BRAF Fusion-positive Low-grade Glioma or Pancreatic Cancer (Perfume)
- Sponsor: National Cancer Center, Japan
- Enrolled: 32

## Sources

- ClinicalTrials.gov NCT06159478: https://clinicaltrials.gov/study/NCT06159478

## Connected records

- cancers: [Pancreatic ductal adenocarcinoma](https://onco.cc/cancers/pancreatic/)
- terms: [Pancreatic cancer trials open today (registry snapshot and UK sites)](https://onco.cc/terms/pancreatic-trials-open-today/)

---
JSON: https://onco.cc/api/v1/entities/nct06159478.json